Shiva P Ponamgi1, Vaibhav R Vaidya2, Christopher V Desimone2, Amit Noheria3, David O Hodge4, Joshua P Slusser5, Naser M Ammash2, Charles J Bruce2, Alejandro A Rabinstein6, Paul A Friedman2, Samuel J Asirvatham2,7. 1. Division of Hospital Internal Medicine, Mayo Clinic Health System, Austin, Minnesota. 2. Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota. 3. Cardiovascular Division, Washington University School of Medicine, St. Louis, Missouri. 4. Department of Health Sciences Research, Mayo Clinic, Jacksonville, Florida. 5. Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota. 6. Department of Neurology, Mayo Clinic, Rochester, Minnesota. 7. Department of Pediatrics and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota.
Abstract
BACKGROUND: Echocardiographically detected patent foramen ovale (PFO) has been associated with stroke/transient ischemic attack (TIA) in patients with cardiac implantable electronic devices (CIEDs). We sought to evaluate the relationship between echocardiographic characteristics and risk of stroke/TIA and mortality in CIED patients with PFO. METHODS: In 6,086 device patients, PFO was detected in 319 patients. A baseline echocardiogram was present in 250 patients, with 186 having a follow-up echocardiogram. RESULTS: Of 250 patients with a baseline echocardiogram, 9.6% (n = 24) had a stroke/TIA during mean follow-up of 5.3 ± 3.1 years; and 42% (n = 105) died over 7.1 ± 3.7 years. Atrial septal aneurysm, prominent Eustachian valve, visible shunting across PFO, baseline or change in estimated right ventricular systolic pressure (RVSP)/tricuspid regurgitation (TR), or maximum RVSP were not associated with postimplant stroke/TIA (P > 0.05). An exploratory multivariate analysis using time-dependent Cox models showed increased hazard of death in patients with increase in TR ≥2 grades (hazard ratio [HR] 1.780, 95% confidence interval [CI] 1.447-2.189, P < 0.0001), or increase in RVSP by >10 mm Hg (HR 2.018, 95% CI 1.593-2.556, P < 0.0001), or maximum RVSP in follow-up (HR 1.432, 95% CI 1.351-1.516, P < 0.0001). A significant increase (P < 0.001) in TR was also noted during follow-up. CONCLUSIONS: In patients with CIED and PFO, structural and hemodynamic echocardiographic markers did not predict future stroke/TIA. However, a significantly higher TR or RVSP was associated with higher mortality.
BACKGROUND: Echocardiographically detected patent foramen ovale (PFO) has been associated with stroke/transient ischemic attack (TIA) in patients with cardiac implantable electronic devices (CIEDs). We sought to evaluate the relationship between echocardiographic characteristics and risk of stroke/TIA and mortality in CIED patients with PFO. METHODS: In 6,086 device patients, PFO was detected in 319 patients. A baseline echocardiogram was present in 250 patients, with 186 having a follow-up echocardiogram. RESULTS: Of 250 patients with a baseline echocardiogram, 9.6% (n = 24) had a stroke/TIA during mean follow-up of 5.3 ± 3.1 years; and 42% (n = 105) died over 7.1 ± 3.7 years. Atrial septal aneurysm, prominent Eustachian valve, visible shunting across PFO, baseline or change in estimated right ventricular systolic pressure (RVSP)/tricuspid regurgitation (TR), or maximum RVSP were not associated with postimplant stroke/TIA (P > 0.05). An exploratory multivariate analysis using time-dependent Cox models showed increased hazard of death in patients with increase in TR ≥2 grades (hazard ratio [HR] 1.780, 95% confidence interval [CI] 1.447-2.189, P < 0.0001), or increase in RVSP by >10 mm Hg (HR 2.018, 95% CI 1.593-2.556, P < 0.0001), or maximum RVSP in follow-up (HR 1.432, 95% CI 1.351-1.516, P < 0.0001). A significant increase (P < 0.001) in TR was also noted during follow-up. CONCLUSIONS: In patients with CIED and PFO, structural and hemodynamic echocardiographic markers did not predict future stroke/TIA. However, a significantly higher TR or RVSP was associated with higher mortality.
Authors: Lawrence G Rudski; Wyman W Lai; Jonathan Afilalo; Lanqi Hua; Mark D Handschumacher; Krishnaswamy Chandrasekaran; Scott D Solomon; Eric K Louie; Nelson B Schiller Journal: J Am Soc Echocardiogr Date: 2010-07 Impact factor: 5.251
Authors: Vaibhav R Vaidya; Christopher V DeSimone; Samuel J Asirvatham; Vishnu M Chandra; Amit Noheria; David O Hodge; Joshua P Slusser; Alejandro A Rabinstein; Paul A Friedman Journal: J Interv Card Electrophysiol Date: 2014-04-27 Impact factor: 1.900
Authors: Christopher V DeSimone; Daniel C DeSimone; Donald J Hagler; Paul A Friedman; Samuel J Asirvatham Journal: Pacing Clin Electrophysiol Date: 2012-10-18 Impact factor: 1.976
Authors: C Weimar; D N Holle; J Benemann; E Schmid; U Schminke; R L Haberl; H-C Diener; M Goertler Journal: Cerebrovasc Dis Date: 2009-07-24 Impact factor: 2.762
Authors: G E D'Alonzo; R J Barst; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; J T Kernis Journal: Ann Intern Med Date: 1991-09-01 Impact factor: 25.391
Authors: Christopher V DeSimone; Paul A Friedman; Amit Noheria; Nikhil A Patel; Daniel C DeSimone; Sami Bdeir; Christopher A Aakre; Vaibhav R Vaidya; Joshua P Slusser; David O Hodge; Michael J Ackerman; Alejandro A Rabinstein; Samuel J Asirvatham Journal: Circulation Date: 2013-08-14 Impact factor: 29.690
Authors: Benjamin S Wessler; David E Thaler; Robin Ruthazer; Christian Weimar; Marco R Di Tullio; Mitchell S V Elkind; Shunichi Homma; Jennifer S Lutz; Jean-Louis Mas; Heinrich P Mattle; Bernhard Meier; Krassen Nedeltchev; Federica Papetti; Emanuele Di Angelantonio; Mark Reisman; Joaquín Serena; David M Kent Journal: Circ Cardiovasc Imaging Date: 2013-11-08 Impact factor: 7.792